Recombinant Zoster Vaccine Associated with a Reduced Risk of Dementia Onset among US Beneficiaries ≥65 Years of Age
There was a statistically significant reduction in the risk of new-onset dementia, AD, and VD associated with a two-dose RZV regimen.
Authors
- Susan dosReis (ORCID: https://orcid.org/0000-0003-2210-6650)
- Driss Oraichi (ORCID: https://orcid.org/0009-0005-1921-7626)
- Sofia B. Pinto (ORCID: https://orcid.org/0000-0001-7758-6706)
- Kareshma Mohanty (ORCID: https://orcid.org/0000-0001-8308-6740)
- Hannah Alsdurf (ORCID: https://orcid.org/0000-0001-9801-7852)
- Abree Johnson
- Kathleen Ryan
- Alejandro Amill‐Rosario
- Phuong Tran
- Huifeng Yun (ORCID: https://orcid.org/0000-0002-0158-1797)
Institutions
- University of Maryland, Baltimore (US)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Brazil) (BR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108646
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00